Business Context and Reporting Period
Company: Niagen Bioscience, Inc. (NAGE)
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2026
Event: Board approval of an increased share repurchase authorization.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital allocation activities.
- Repurchase Authorization: Increased to $20.0 million.
- Previous Authorization: $10.0 million (approved October 31, 2025).
- Shares Repurchased to Date: Approximately $2.6 million (as of March 17, 2026).
- Remaining Capacity: Approximately $17.4 million under the new authorization.
Material Changes
The Board of Directors doubled the authorized amount for the share repurchase program from $10.0 million to $20.0 million. This change was made to provide additional flexibility to return capital to stockholders and to repurchase shares at attractive prices depending on market conditions.
Guidance, Outlook, and Risks
Program Terms: The program is expected to remain in effect for the previously approved 24-month period unless earlier completed, suspended, modified, or terminated by the Board.
Execution Method: Repurchases may occur in the open market, through privately negotiated transactions, or pursuant to a Rule 10b5-1 trading plan.
Risks and Contingencies: The program does not obligate the Company to acquire any specific amount of shares. The timing, number, and value of shares repurchased depend on market conditions, trading price, corporate requirements, and regulatory factors. The program may be suspended or discontinued at any time.
Investor Verification Checklist
- Verify the exact number of shares repurchased for the $2.6 million spent to date in subsequent periodic reports (10-Q/10-K).
- Monitor the Company's cash position to ensure sufficient liquidity to fund the full $20.0 million authorization.
- Review future 8-K filings for any suspension, modification, or termination of the repurchase program.
- Check for the adoption of a Rule 10b5-1 trading plan in future disclosures.